ストックスクリーナーアプリを入手
13.71
0.07%
0.01
アフターアワーズ：
13.72
0.010
+0.07%
前日終値:
$13.70
開ける：
$13.71
24時間の取引高:
2.10M
Relative Volume:
0.80
時価総額：
$3.60B
収益：
$6.16B
当期純損益:
$246.00M
株価収益率:
14.61
EPS:
0.9387
ネットキャッシュフロー:
$708.00M
1週間 パフォーマンス:
-0.07%
1か月 パフォーマンス:
-0.36%
6か月 パフォーマンス:
+123.29%
1年 パフォーマンス:
+24.75%
1日の値動き範囲:
$13.71
$13.74
1週間の範囲:
$13.70
$13.76
52週間の値動き範囲:
$5.69
$13.79
Organon Co Stock (OGN) Company Profile
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.71 | 3.61B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,149.85 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.66 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.93 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.81 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.05 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-10-27 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-09-06 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-11-03 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-21 | 開始されました | Barclays | Overweight |
| 2023-03-16 | 開始されました | Raymond James | Outperform |
| 2022-10-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 開始されました | Piper Sandler | Neutral |
| 2021-09-01 | 開始されました | BofA Securities | Buy |
| 2021-07-22 | 開始されました | Citigroup | Buy |
| 2021-06-15 | 開始されました | JP Morgan | Neutral |
| 2021-06-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Organon Co (OGN) 最新ニュース
Organon presents VTAMA analysis: Organon stock gains 1.16 percent - AD HOC NEWS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Tangible book value per share of Organon & Co. – HAN:7XP - TradingView
Organon & Co. Revenue Breakdown – HAN:7XP - TradingView
Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - ETPharma.com
Sun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report - NDTV Profit
Sun Pharma plans $1 billion rupee debt sale to refinance Organon acquisition loan - Firstpost
Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis - marketscreener.com
Sun Pharma’s Biggest Global Bet, Buys Organon in $11.75 Billion Deal; Pharma Stock Surge 7%Time to Buy? - goodreturns.in
Organon & Co. (OGN) Stock forecasts - Yahoo Finance Singapore
Precision Trading with Organon & Co. (OGN) Risk Zones - Stock Traders Daily
Why Organon (OGN) Is Getting Attention Today - Yahoo Finance
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Organon (OGN) Looks 22% Overvalued Following The MIUDELLA FDA Filing - simplywall.st
Class A Dig — Organon/Sun Pharma premature-close (May ACQ deleted; early-2027 expected) - app.dealroom.co
Organon (OGN) Wins FDA Review Acceptance For New Hormone Free Contraceptive - simplywall.st
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com - Investing.com Canada
Organon Backs Women’s Health Efforts Across India - pharmacy.biz
Organon Korea, Boryung expand Atozet tie-up to co-promotion - koreabiomed.com
Organon & Co. Common Stock (NY: OGN - The Chronicle-Journal
ORGANON & CO.MIUDELLA ANTICIPATED TO BE COMMERCIALLY AVAILABLE IN LATE 2026 - Moomoo
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA - Business Wire
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Organon: A Merger-Arbitrage Hold With Limited Upside - Seeking Alpha
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Sun Pharma Gets Investment-Grade Ratings From Moody's, S&P for USD 11.75 Bn Organon Deal - Medical Dialogues
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - Business Standard
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sun Pharma receives ratings boost over USD 11.75-billion Organon acqui - Daily Pioneer
Sun Pharma Gets Ratings Boost From Moody's, S&P Over $11.75-Bn Organon & Co Acquisition Bid - outlookbusiness.com
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid - BusinessLine
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid - ET Manufacturing
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma Gets Ratings Boost After Organon Acquisition Bid - Rediff MoneyWiz
Organon & Co. (OGN) Edges Up 0.15% to $13.78 as Shares Trade Between Key Support and ResistanceExtension Target - careplusvn.com
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Nigeria
Organon & Co stock hits 52-week high at $13.78 - Investing.com India
Henlius - henlius.com
Organon earnings up next: Can drugmaker rebound after Q1 miss? - investing.com
Organon (OGN) Move: Ends Up by 0.07% at $13.74 on the Day; Technical Setup: the $13.05 to $14.43 Range Remains in FocusBox Spread - Vinanet
Sun Pharma completes $11.75bn financing syndication for Organon acquisition - Generics and Biosimilars Initiative
Organon (OGN) Trading: Ends Up by 0.37% at $13.73 at the Close; Next Session: the Supplied Trading Band Runs From $13.04 to $14.42 under the Current SnapshotOvernight Profile - Vinanet
Organon & Co stock hits 52-week high at 13.73 USD - Investing.com
Organon & Co. (NYSE:OGN) Reaches New 12-Month HighStill a Buy? - MarketBeat
Orographic Financial Advisors, LLC's Organon & Co(OGN) Holding History - GuruFocus
how InvestingPro’s Fair Value spotted Organon’s 69% gain potential By Investing.com - Investing.com South Africa
Organon Co (OGN) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
大文字化:
|
ボリューム (24 時間):